Furthermore, increased SNHG3 levels correlated with shorter OS (HR = 3.02, 95% CI: 1.16–7.86, p = 0.028) and BMFS (HR = 2.41, 95% CI: 1.03–5.61, p = 0.04) in prostate cancer patients, as demonstrated by in-house tissue samples. This evidence concerns the gene SNHG3 and prostate cancer.